Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field